跳至主要内容
临床试验/NCT02298634
NCT02298634撤回不适用

Biomarker for Farber Disease - An International, Multicenter, Epidemiological Protocol

CENTOGENE GmbH Rostock3 个研究点 分布在 3 个国家开始时间: 2018年8月20日最近更新:
适应症

试验速览

阶段
不适用
状态
撤回
发起方
试验地点
3
主要终点
Sequencing of the Farber disease related gene

研究概览

简要总结

Development of a new mass spectrometry-based biomarker for the early and sensitive diagnosis of Farber disease from the blood

详细描述

Farber disease (FD), also known as Farber's lipogranulomatosis, is an autosomal recessive lysosomal storage disease marked by a deficiency in enzyme ceramidase which causes a progressive accumulation of fatty material lipids leading to abnormalities in the joints, liver, throat, tissues and central nervous system.

FD is an extremely rare disorder, with a prevalence of less than 1/1000000. Currently only about 80 cases are reported worldwide. Disease onset is typically in early infancy but may occur later in life.

FD is caused by a mutation in the ASAH1 gene, situated on the short arm of chromosome 8. This gene codes for acid ceramidase, a lysosomal heterodimeric enzyme that hydrolyzes ceramide into sphingosine and fatty acid. To date, less than 25 distinct mutations have been identified in Farber patients, but no large deletions have yet been reported. It is inherited with an autosomal recessive pattern.

The clinical presentation of FD is characterized by the appearance of subcutaneous skin nodules, ordinarily near the joints, most often interphalangeal, wrist, elbow and ankle joints, or over points of mechanical pressure. These manifestations are very painful and lead to progressive joint stiffness, limitation of motion by contractures and finally to immobilization and deformation of joints. Also, a characteristic sign of FD is the development of a progressive hoarseness due to laryngeal involvement.

Beside these major manifestations seven phenotypes have been described which differ in severity and additional organ involvement, like the lungs, nervous system, heart and lymph nodes. Dependent on residual lysosomal ceramidase turnover, patients have a variable degree of central nervous system disease, leading to progressive neurologic deterioration. In most cases the neuronal dysfunction rather than the general physical dystrophy seems to limit the duration of FD. As well, patients with FD may die due to pulmonary disease with interstitial pneumonia.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
2 Months 至 —(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

结局指标

主要结局

Sequencing of the Farber disease related gene

时间窗: 4 weeks

Next-Generation Sequencing (NGS) of the ASAH1 gene will be performed. The mutation will be confirmed by Sanger sequencing.

次要结局

  • The Farber disease specific biomarker candidates finding(24 months)

研究者

发起方
CENTOGENE GmbH Rostock
申办方类型
Industry
责任方
Sponsor

研究点 (3)

Loading locations...

相似试验

Biomarker for Farber Disease (BioFarber) | 临床试验